Scarica l'app Stockscreener
1.46
5.04%
0.07
Precedente Chiudi:
$1.39
Aprire:
$1.41
Volume 24 ore:
354.93K
Relative Volume:
0.72
Capitalizzazione di mercato:
$153.80M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-3.8543
EPS:
-0.3788
Flusso di cassa netto:
$21.84M
1 W Prestazione:
-2.67%
1M Prestazione:
-10.98%
6M Prestazione:
-27.72%
1 anno Prestazione:
-35.68%
Intervallo 1D:
$1.41
$1.54
Intervallo di 1 settimana:
$1.33
$1.5528
Portata 52W:
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.46 | 146.43M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
Can ProQR Therapeutics N.V. withstand a market correctionCPI Data & Community Verified Watchlist Alerts - mfd.ru
Is ProQR Therapeutics N.V. currently under institutional pressureChart Signals & Long-Term Growth Portfolio Plans - mfd.ru
Will ProQR Therapeutics N.V. stock recover after earningsPortfolio Gains Summary & Weekly High Conviction Trade Ideas - mfd.ru
A | Is ProQR Therapeutics N.V. stock showing strong momentumJuly 2025 Levels & Risk Controlled Swing Alerts - mfd.ru
Aug Levels: Is ProQR Therapeutics NV stock a buy or sellJuly 2025 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ProQR announces board changes as two members set to depart By Investing.com - Investing.com South Africa
ProQR announces board changes as two members set to depart - Investing.com
ProQR Therapeutics (PRQR) Announces Board Changes at Upcoming AG - GuruFocus
ProQR Announces Planned Changes to Board Composition - markets.businessinsider.com
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM - TipRanks
Co-founder among 2 ProQR directors set to leave board at 2026 AGM - Stock Titan
ProQR Therapeutics NV Announces Departure of Board Members Dinko Valerio and Alison Lawton - Longbridge
Myriad Genetics (NASDAQ:MYGN) & ProQR Therapeutics (NASDAQ:PRQR) Head-To-Head Survey - Defense World
ProQR Aktie: Pipeline-Fortschritte - Börse Global
Risk Recap: Will ProQR Therapeutics NV stock recover after earningsJuly 2025 Highlights & Capital Efficient Trading Techniques - baoquankhu1.vn
Dip Buying: Is Sharps Technology Inc Equity Warrant in a bullish channelWeekly Market Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Gains Recap: Is ProQR Therapeutics NV a cyclical or defensive stockEarnings Trend Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Quarterly Earnings: Can ProQR Therapeutics NV weather a recessionWeekly Stock Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 28% - 富途牛牛
Aug PreEarnings: Is KFFB stock undervalued right nowTrade Entry Report & Weekly Stock Performance Updates - baoquankhu1.vn
Market Recap: Can SBEV be recession proofQuarterly Trade Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharm - Barchart.com
Earnings Miss: Can ProQR Therapeutics NV reach resistance levels soon2025 AllTime Highs & Expert Verified Movement Alerts - baoquankhu1.vn
Trading Recap: Is Alumis Inc gaining market shareJuly 2025 Market Mood & Growth Focused Entry Point Reports - baoquankhu1.vn
Day Trade: Does OLMA have strong EBITDA marginsJuly 2025 Volume & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Published on: 2026-01-18 21:01:57 - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Aug Patterns: What insider trading reveals about ProQR Therapeutics NV stockProfit Target & Consistent Growth Equity Picks - Bộ Nội Vụ
Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - simplywall.st
Working capital per share of ProQR Therapeutics N.V. – FWB:0PQ - TradingView — Track All Markets
ProQR reports positive initial AX-0810 safety data in phase 1 trial - Investing.com Nigeria
Will ProQR Therapeutics N.V. stock deliver long term returnsDip Buying & Free Community Consensus Stock Picks - ulpravda.ru
ProQR stock falls after initial AX-0810 data, pipeline updates By Investing.com - Investing.com Australia
Why ProQR Therapeutics N.V. (0PQ) stock stays undervalued2025 Price Momentum & Weekly Stock Breakout Alerts - ulpravda.ru
Why ProQR Therapeutics N.V. stock is a value investor pick2025 Pullback Review & Risk Adjusted Swing Trade Ideas - Улправда
ProQR stock falls after initial AX-0810 data, pipeline updates - Investing.com
ProQR announces encouraging AX-0810 phase 1 - MarketScreener
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans - TipRanks
ProQR reports positive initial AX-0810 safety data in phase 1 trial By Investing.com - Investing.com South Africa
ProQR (PRQR) details encouraging AX-0810 Phase 1 data and 2026 plans - Stock Titan
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Why ProQR Therapeutics N.V. stock is considered a top pickCapital Gains Strategies & Create Passive Income With Smart Stocks - ulpravda.ru
ProQR Therapeutics N.V. (PRQR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions - Yahoo Finance
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can ProQR Therapeutics N.V. (0PQ) stock sustain double digit ROEJuly 2025 Review & Free Technical Confirmation Trade Alerts - Улправда
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):